Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution
- PMID: 25388289
- DOI: 10.1002/cncy.21477
Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution
Abstract
Background: At a high-volume center, it became necessary to provide benchmarks for the accuracy and risk of malignancy per urine cytology diagnostic category. The additive sensitivity for the determination of the residual risk of disease was calculated with the goal of determining the performance of cytology and optimal triage, including the number of urine samples, before the detection of malignancy in surveillance patients.
Methods: A 2-year laboratory information system-based search was conducted, and it yielded 587 subjects (695 biopsy and cytology pairs) with histological follow-up. The sensitivity and specificity of cytology for urothelial malignancy, the risk of malignancy per diagnostic category, the additive sensitivity, and the time for conversion from a negative initial cytology result to a positive cytology result were examined.
Results: The overall average sensitivity and specificity of cytology were 48.9% and 83.0%, respectively. The additive sensitivity increased with each subsequent cytology and peaked with the third cytology. A median conversion time of 22.2 months from a negative initial cytology result to a positive cytology result and a decline in predictive positive cytology after the fourth cytology were noted. Subcategorization of the atypical category failed to show statistical significance in predicting outcomes of biopsy. Surveillance subjects, as compared to primary subjects, showed a higher sensitivity for the detection of high and low grade cancers.
Conclusions: The findings suggest that atypia favoring malignancy is being appropriately flagged. However, further definition of the atypical category is needed to increase specificity with a better qualitative or quantitative morphological algorithm. This study provides a risk of malignancy for each category for benchmarking and clinical triage. The data suggest that follow-up should include at least 4 consecutive urine specimens over a period of 22.2 months.
Keywords: ROC curve; additive sensitivity; median conversion time; risk of malignancy; urine cytology.
© 2015 American Cancer Society.
Similar articles
-
Evaluation of atypical urine cytology progression to malignancy.Cancer Cytopathol. 2013 Jul;121(7):387-91. doi: 10.1002/cncy.21278. Epub 2013 Mar 27. Cancer Cytopathol. 2013. PMID: 23536358
-
Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?Scand J Urol Nephrol. 2002;36(3):213-7. doi: 10.1080/003655902320131901. Scand J Urol Nephrol. 2002. PMID: 12201938
-
Is the performance of urinary cytology as high as reported historically? A contemporary analysis in the detection and surveillance of bladder cancer.Urol Oncol. 2014 Jan;32(1):27.e1-6. doi: 10.1016/j.urolonc.2012.09.011. Epub 2013 Feb 12. Urol Oncol. 2014. PMID: 23410943
-
UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.Ann Pathol. 2012 Dec;32(6):e52-6, 438-43. doi: 10.1016/j.annpat.2012.09.207. Epub 2012 Nov 24. Ann Pathol. 2012. PMID: 23244486 Review. English, French.
-
The use of urine cytology for diagnosing bladder cancer in spinal cord injured patients.J Urol. 1997 Jun;157(6):2112-4. J Urol. 1997. PMID: 9146593 Review.
Cited by
-
Usefulness of the Urine Methylation Test (Bladder EpiCheck®) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells-An Institutional Study.J Clin Med. 2022 Jul 3;11(13):3855. doi: 10.3390/jcm11133855. J Clin Med. 2022. PMID: 35807141 Free PMC article.
-
Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.J Cancer Res Clin Oncol. 2017 Sep;143(9):1757-1769. doi: 10.1007/s00432-017-2433-3. Epub 2017 May 8. J Cancer Res Clin Oncol. 2017. PMID: 28484844 Free PMC article. Clinical Trial.
-
A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.Clin Epigenetics. 2021 Apr 26;13(1):91. doi: 10.1186/s13148-021-01073-x. Clin Epigenetics. 2021. PMID: 33902700 Free PMC article.
-
Impact of Implementing Paris System on Diagnostic Precision and Management of Urinary Bladder Neoplasms.Indian J Surg Oncol. 2024 Jun;15(2):225-235. doi: 10.1007/s13193-023-01864-z. Epub 2024 Jan 4. Indian J Surg Oncol. 2024. PMID: 38741619 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical